Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Epigenetic Regulation

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Autocrine TGFβ2 enforces a transcriptionally hybrid cell state in Ewing sarcoma.

Science advances·2026

Same author

Armoring STEAP1 CAR T cells with IL-18 potentiates antitumor activity in Ewing sarcoma.

bioRxiv : the preprint server for biology·2025

Same author

SGSS05-NS3, a covalent SETD8 inhibitor that activates p53 pathway in neuroblastoma.

Journal of experimental & clinical cancer research : CR·2025

Same author

Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies.

Pediatric blood & cancer·2025

Same author

Menin inhibition impairs metastatic colonization of Ewing sarcoma.

bioRxiv : the preprint server for biology·2025

Same author

GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts.

Molecular therapy. Oncology·2025

Search research articles

Related Experiment Video

Updated: May 22, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Epigenetic changes in pediatric solid tumors: promising new targets.

Elizabeth R Lawlor¹, Carol J Thiele

¹Department of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, USA. elawlor@umich.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|May 17, 2012

Summary

Epigenetic deregulation, driven by histone code and chromatin modifier gene alterations, is key in pediatric solid tumors. Understanding these mechanisms offers new pathways for targeted cancer therapies.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Experiment Videos

Last Updated: May 22, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Area of Science:

Oncology
Epigenetics
Developmental Biology

Background:

Cancer is increasingly understood through the lens of epigenetics, particularly the histone code and gene regulation during development.
Whole cancer genome sequencing reveals frequent somatic mutations and deregulated expression of chromatin-modifying enzymes.
Pediatric embryonal solid tumors are a critical area where these epigenetic insights are highly relevant.

Purpose of the Study:

To review how alterations in transcriptional machinery and chromatin modifier genes initiate and progress pediatric solid tumors.
To discuss the convergence of classic genetic alterations on the epigenome in these tumors.
To highlight novel therapeutic avenues emerging from understanding epigenetic deregulation in cancer.

Main Methods:

Review of current literature on cancer epigenetics, focusing on pediatric solid tumors.
Analysis of findings from whole cancer genome sequencing studies.
Integration of knowledge regarding the histone code and epigenetic regulation.

Main Results:

Somatic mutations and altered expression of chromatin-modifying enzymes are frequently observed in pediatric solid tumors.
Genetic alterations in these tumors converge on the epigenome, disrupting developmental gene programs.
Epigenetic deregulation plays a crucial role in the initiation and progression of pediatric solid tumors.

Conclusions:

Alterations in chromatin modifiers and transcriptional machinery are central to pediatric solid tumor development.
A deeper understanding of epigenetic mechanisms provides a foundation for developing targeted cancer therapies.
The epigenome is a critical target for future therapeutic strategies in pediatric oncology.